METTL3 and breast cancer: Further survival studies demonstrated that the BC patients acquiring mutated METTL3 had the most significant survival benefits after NAC treatment as compared to the patients acquiring wild-type METTL3. This prompted us to further discuss the role of METTL3 in predicting the NAC response in cancer patients.